SUBSCRIBE
SUBSCRIBE
News   Policy

Spectrum Pharmaceuticals, Inc. Says FDA Extends Review Date of Cancer Drug

February 23, 2009 | 
1 min read
Feb 23 (Reuters) - Spectrum Pharmaceuticals said U.S. regulators have extended the review date of its experimental cancer drug, Zevalin, to July 2.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Flat 3d isometric business people came from different way but have same target. Business team and target concept.
Insights
Single Pivotal Trials Demand Stronger Data and Risk Strategies
March 10, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Background with halftone hand hold magnifier and torn papers. Collage element for search concept. Find information in internet browser.
Adcomms
Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months
March 9, 2026
 · 
3 min read
 · 
Tristan Manalac
The white plane flies against the blue sky, leaving a white trail. Vector illustration
Rare diseases
Prasad’s Departure Could Be ‘Big Win’ for Biotech—Especially Rare Disease Space: Analysts
March 9, 2026
 · 
3 min read
 · 
Tristan Manalac
halftone magazine style banner, dislike, negative rating, hand thumbs down
Complete response letters
Incyte’s Lung Cancer Expansion Bid Thwarted by Issues at Novo’s Catalent-Acquired Site
March 9, 2026
 · 
2 min read
 · 
Tristan Manalac